A new pharmaceutical initiative in Senegal is putting the spotlight on Africa’s growing effort to produce essential medicines within the continent.
Teranga Pharma has begun local manufacturing of DREPAF, a generic version of hydroxyurea used in the management of sickle cell disease.
The initiative comes with an estimated investment of 4 billion CFA francs, or about US$7.1 million, in a pharmaceutical facility in Mbao, close to Senegal’s capital, Dakar.
For patients and families affected by sickle cell disease, the development could have practical importance if local production helps maintain a stable and affordable supply of the medicine.
But the significance of the project extends beyond sickle cell treatment.
It also raises a broader question about Africa’s ability to reduce its dependence on imported medicines and build a stronger pharmaceutical manufacturing sector.
An Existing Medicine Produced Closer to Patients
DREPAF is not a newly discovered treatment.
It is based on hydroxyurea, a medicine that has been used internationally in the management of sickle cell disease.
Hydroxyurea can increase fetal haemoglobin levels and, for appropriate patients, help reduce the frequency of painful crises and some other complications associated with sickle cell disease.
The treatment must, however, be used under medical supervision.
Sickle cell disease requires long-term care, and effective management can involve early diagnosis, regular monitoring, appropriate medication, blood transfusion services and treatment of complications.
Therefore, the significance of Senegal’s initiative lies primarily in access to an established treatment, rather than the discovery of a cure.
The Price Question
For families dealing with a lifelong medical condition, affordability is often just as important as the availability of an effective treatment.
DREPAF has reportedly been priced at about 3,000 CFA francs for the 500mg formulation, while the 100mg paediatric formulation is reportedly around 1,500 CFA francs.
Whether those prices will remain affordable over time will depend on production costs, distribution, healthcare policies and the ability of the manufacturer to maintain supply.
Local manufacturing could reduce some dependence on international pharmaceutical supply chains, but it is not a guarantee that every patient will immediately have easier access to treatment.
Distribution will be particularly important.
A medicine produced in Dakar still needs to reach patients in other parts of Senegal and, potentially, other African countries.
Senegal Joins a Wider African Effort
Senegal’s move is part of a much broader effort across Africa to improve the prevention and treatment of sickle cell disease.
Countries including Nigeria and Ghana have expanded screening and specialist treatment initiatives, while research programmes involving several African countries have examined ways to improve early diagnosis and access to hydroxyurea.
Local pharmaceutical production is another part of that response.
Nigeria, for example, has also had locally produced hydroxyurea, showing that African pharmaceutical companies are increasingly looking at the possibility of manufacturing treatments for diseases that disproportionately affect African populations.
The more countries develop domestic production capacity, the greater the potential for regional pharmaceutical cooperation.
Ambitions Beyond Senegal
Teranga Pharma’s reported plans could make the project even more significant.
The company has indicated an interest in supplying DREPAF to markets including Burkina Faso, Guinea, Côte d’Ivoire, the Democratic Republic of Congo, Gabon and Cameroon.
If regulatory approvals, manufacturing capacity and distribution arrangements allow that expansion to happen, the medicine could become part of a wider regional supply chain.
Such a development would support the idea of African countries increasingly sourcing essential medicines from manufacturers within the continent.
What Success Would Look Like
The ultimate test of the project will not simply be whether a factory can produce the medicine.
Success will depend on whether patients can reliably obtain it when they need it.
That means maintaining production, ensuring quality, keeping prices within reach of patients, expanding distribution and ensuring that people with sickle cell disease receive proper medical supervision.
There is also the larger question of whether similar investments can be made in medicines for other diseases affecting African communities.
Senegal’s DREPAF project therefore represents more than one pharmaceutical product.
It is an example of the type of local manufacturing capacity that could gradually reshape healthcare across Africa.
The continent still faces major gaps in pharmaceutical production, but initiatives such as this demonstrate the potential for African companies to play a greater role in producing medicines for African patients.
For people living with sickle cell disease, the hope is simple: a reliable supply of an effective treatment, available closer to home and at a price families can afford.
